同和药业(300636)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300636 同和药业

已收盘 04-17 15:00:00

{"stockData":{"symbol":"300636","market":"SZ","secType":"STK","nameCN":"同和药业","latestPrice":8.05,"timestamp":1776409401000,"preClose":8.18,"halted":0,"volume":7536800,"delay":0,"changeRate":-0.0159,"floatShares":367000000,"shares":420000000,"eps":0.2251,"marketStatus":"已收盘","change":-0.13,"latestTime":"04-17 15:00:00","open":8.16,"high":8.16,"low":7.96,"amount":60523400,"amplitude":0.0244,"askPrice":8.06,"askSize":145,"bidPrice":8.05,"bidSize":997,"shortable":0,"etf":0,"ttmEps":0.2251,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776648600000},"marketStatusCode":5,"adr":0,"adjPreClose":8.18,"symbolType":"stock","openAndCloseTimeList":[[1776389400000,1776396600000],[1776402000000,1776409200000]],"highLimit":9,"lowLimit":7.36,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":419951495,"isCdr":false,"pbRate":1.45,"roa":"--","peRate":35.761884,"roe":"3.56%","epsLYR":0.2538,"committee":0.2047,"marketValue":3381000000,"turnoverRate":0.0205,"status":1,"floatMarketCap":2957000000},"requestUrl":"/m/hq/s/300636/tweets","defaultTab":"tweets","newsList":[{"id":"2622184939","title":"3月27日同和药业涨5.04%，湘财医药健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2622184939","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622184939?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:17","pubTimestamp":1774599446,"startTime":"0","endTime":"0","summary":"证券之星消息，3月27日同和药业涨5.04%，收盘报7.92元，换手率2.47%，成交量9.09万手，成交额7091.6万元。重仓同和药业的公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为湘财基金的湘财医药健康混合A。湘财医药健康混合A目前规模为0.16亿元，最新净值1.6505，较上一交易日上涨0.0%，近一年上涨37.15%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700033471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614470000","title":"同和药业最新公告：公司原料药“富马酸伏诺拉生”通过CDE审批","url":"https://stock-news.laohu8.com/highlight/detail?id=2614470000","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614470000?lang=zh_cn&edition=full","pubTime":"2026-02-25 18:10","pubTimestamp":1772014252,"startTime":"0","endTime":"0","summary":"同和药业(300636.SZ)公告称，公司提交的“富马酸伏诺拉生”原料药通过了国家药品监督管理局药品审评中心（CDE）审批，已批准在国内上市制剂中使用。该原料药主要用于治疗反流性食管炎，通过CDE审批有利于公司拓展产品在国内市场的销售，形成国内外市场同步销售的良好格局。但具体销售情况存在一定不确定性，公司将履行信息披露义务。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500031452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610926478","title":"同和药业：CMO/CDMO业务有望在2027、2028年实现快速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2610926478","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610926478?lang=zh_cn&edition=full","pubTime":"2026-02-12 20:53","pubTimestamp":1770900790,"startTime":"0","endTime":"0","summary":"公司明确表示承接跨国药企的CMO业务，并服务于原研公司。近年公司在CMO/CDMO项目上新增项目有所增多，在部分老项目逐渐退出市场的情况下，公司将积极服务现有项目，大力开拓新项目，争取新项目能早日放量以弥补现有老项目订单减少带来的缺口。CMO/CDMO业务有望在2027、2028年实现快速增长。公司将密切关注AI技术的发展，根据行业特点及公司的实际情况，积极推动AI技术在研发和生产的应用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200037738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608352963","title":"同和药业(300636.SZ)：甲苯磺酸艾多沙班原料药通过CDE审批","url":"https://stock-news.laohu8.com/highlight/detail?id=2608352963","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608352963?lang=zh_cn&edition=full","pubTime":"2026-02-04 17:48","pubTimestamp":1770198539,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同和药业(300636.SZ)公告，公司提交的“甲苯磺酸艾多沙班”原料药通过了CDE审批。甲苯磺酸艾多沙班是一种口服抗凝药物，主要用于预防非瓣膜性房颤患者的卒中及全身性栓塞，以及治疗或预防深静脉血栓和肺栓塞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401609.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CDE","BK4017","LU1223082519.USD","BK0239","300636","LU1223082196.USD","LU1223083913.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607741725","title":"股市必读：同和药业（300636）1月28日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2607741725","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607741725?lang=zh_cn&edition=full","pubTime":"2026-01-29 02:38","pubTimestamp":1769625494,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘，同和药业报收于8.2元，下跌3.53%，换手率3.1%，成交量11.4万手，成交额9485.96万元。董秘最新回复投资者： 董秘您好，想向您咨询以下几个问题： 1.公司当前最新的销售毛利率与净利率分别是多少？当日关注点来自交易信息汇总：1月28日主力资金净流出412.64万元，散户资金净流入346.09万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900001493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606793559","title":"同和药业：2026年公司二厂区二期试生产的两个车间正式投产后，年产能可达15-16亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606793559","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606793559?lang=zh_cn&edition=full","pubTime":"2026-01-28 15:42","pubTimestamp":1769586126,"startTime":"0","endTime":"0","summary":"证券之星消息，同和药业01月28日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，想向您咨询以下几个问题： 1.公司当前最新的销售毛利率与净利率分别是多少？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800021697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601594838","title":"同和药业（300636）披露2025年度持续督导定期现场检查报告，1月5日股价上涨2.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601594838","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601594838?lang=zh_cn&edition=full","pubTime":"2026-01-05 23:17","pubTimestamp":1767626233,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，同和药业报收于7.66元，较前一交易日上涨2.0%，最新总市值为32.17亿元。该股当日开盘7.5元，最高7.68元，最低7.49元，成交额达4524.95万元，换手率为1.62%。近日，招商证券股份有限公司发布了关于江西同和药业股份有限公司2025年度持续督导定期现场检查报告。公司业绩无大幅波动，与同行业比较无明显异常，股东及公司承诺均得到完全履行。现场检查未发现重大问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500041079.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589576897","title":"同和药业：公司仅在定期报告中披露截至报告期末的股东人数","url":"https://stock-news.laohu8.com/highlight/detail?id=2589576897","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589576897?lang=zh_cn&edition=full","pubTime":"2025-12-05 20:04","pubTimestamp":1764936240,"startTime":"0","endTime":"0","summary":"证券日报网讯 12月5日，同和药业在互动平台回答投资者提问时表示，为保证所有投资者平等获悉公司信息，公司仅在各定期报告中披露截至报告期末的股东人数情况。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-05/doc-infzuert9398534.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-05/doc-infzuert9398534.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","300636"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588423087","title":"同和药业：新产能扩建已有潜在客户","url":"https://stock-news.laohu8.com/highlight/detail?id=2588423087","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588423087?lang=zh_cn&edition=full","pubTime":"2025-12-02 15:18","pubTimestamp":1764659905,"startTime":"0","endTime":"0","summary":"证券之星消息，同和药业(300636)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问：周总，请问下公司新产能扩建是否是已有潜在客户，或者已取得客户合作的前提下开展的？谢谢同和药业回复：对的。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200017062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2582210153","title":"同和药业（300636）披露2025年第一次临时股东大会决议公告，11月12日股价上涨0.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582210153","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582210153?lang=zh_cn&edition=full","pubTime":"2025-11-12 17:35","pubTimestamp":1762940140,"startTime":"0","endTime":"0","summary":"截至2025年11月12日收盘，同和药业报收于8.48元，较前一交易日上涨0.36%，最新总市值为35.61亿元。近日，江西同和药业股份有限公司发布2025年第一次临时股东大会决议公告。公告显示，公司于2025年11月11日召开2025年第一次临时股东大会，审议通过了《关于修订<公司章程>的议案》及多项制度修订与制定议案，包括股东会议事规则、董事会议事规则、独立董事制度等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200028802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2580626792","title":"同和药业(300636.SZ)通过美国FDA现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2580626792","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580626792?lang=zh_cn&edition=full","pubTime":"2025-11-03 16:51","pubTimestamp":1762159868,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同和药业(300636.SZ)公告，公司于2025年8月4日至2025年8月7日接受了美国食品药品监督管理局(“美国FDA”)的cGMP(现行药品生产质量管理规范)现场检查，检查范围涵盖质量体系、物料、生产、包装与标签、设备设施、实验室控制六大系统。近日，公司从美国FDA官网获悉公司已通过了上述现场检查，符合美国FDA的cGMP管理规范。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2578657993","title":"股市必读：同和药业(300636)股东户数1.55万户，较上期减少3.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578657993","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578657993?lang=zh_cn&edition=full","pubTime":"2025-10-27 04:50","pubTimestamp":1761511816,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，同和药业报收于8.8元，上涨1.62%，换手率3.28%，成交量12.05万手，成交额1.06亿元。来自公司公告汇总：同和药业将于2025年11月11日召开第一次临时股东大会，审议《关于修订<公司章程>的议案》等多项制度修订事项。股本股东变化股东户数变动截至2025年9月30日，公司股东户数为1.55万户，较6月30日减少482.0户，减幅为3.02%。表决结果均为3票同意，0票反对，0票弃权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700001328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2577517098","title":"同和药业（300636）披露召开2025年第一次临时股东大会通知，10月24日股价上涨1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577517098","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577517098?lang=zh_cn&edition=full","pubTime":"2025-10-24 22:27","pubTimestamp":1761316043,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，同和药业报收于8.8元，较前一交易日上涨1.62%，最新总市值为36.96亿元。该股当日开盘8.61元，最高8.93元，最低8.57元，成交额达1.06亿元，换手率为3.28%。公司近日发布公告称，江西同和药业股份有限公司将于2025年11月11日召开2025年第一次临时股东大会，会议由公司董事会召集，现场会议时间为当日15:00，网络投票时间为9:15至15:00。股权登记日为2025年11月5日。参会人员食宿及交通费用自理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400042910.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518045797","title":"同和药业最新公告：公司原料药恩格列净通过药品GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2518045797","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518045797?lang=zh_cn&edition=full","pubTime":"2025-03-11 17:10","pubTimestamp":1741684207,"startTime":"0","endTime":"0","summary":"同和药业(300636.SZ)公告称，公司于近日收到江西省药品监督管理局的药品GMP符合性检查结果告知书，获悉公司本次检查原料药恩格列净符合药品GMP。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031100029949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518792210","title":"同和药业(300636.SZ)通过药品GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2518792210","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518792210?lang=zh_cn&edition=full","pubTime":"2025-03-11 17:08","pubTimestamp":1741684087,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同和药业(300636.SZ)公告，公司于近日收到江西省药品监督管理局的“江西省药品监督管理局药品GMP符合性检查结果告知书(赣药品GMP(2025)第A0020号)”，获悉经现场检查和综合评定,公司本次检查原料药恩格列净符合药品GMP。恩格列净适用于治疗2型糖尿病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512714761","title":"同和药业(300636.SZ)：恩格列净获韩国药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2512714761","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512714761?lang=zh_cn&edition=full","pubTime":"2025-02-19 17:51","pubTimestamp":1739958679,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同和药业(300636.SZ)公告，公司近日收到韩国食品药品安全部(MFDS)颁发的恩格列净药品注册证书，恩格列净适用于治疗2型糖尿病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1251712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512746421","title":"同和药业最新公告：公司恩格列净原料药获得韩国药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2512746421","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512746421?lang=zh_cn&edition=full","pubTime":"2025-02-19 17:51","pubTimestamp":1739958663,"startTime":"0","endTime":"0","summary":"同和药业公告称，公司收到韩国食品药品安全部颁发的恩格列净原料药药品注册证书，标志着公司恩格列净原料药获得了韩国市场的准入资格，将对公司进一步扩大国际市场业务起到积极作用。但医药产品销售易受市场环境变化、汇率波动等因素影响，投资者需谨慎决策，注意投资风险。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021900032614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512843945","title":"同和药业(300636.SZ)：米拉贝隆取得韩国药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2512843945","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512843945?lang=zh_cn&edition=full","pubTime":"2025-02-17 18:33","pubTimestamp":1739788437,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同和药业(300636.SZ)公告，公司近日收到韩国食品药品安全部(MFDS)颁发的米拉贝隆药品注册证书。米拉贝隆是一种选择性β3-肾上腺受体激动剂，可通过激活膀胱逼尿肌上的β3-肾上腺受体而提高膀胱充盈和贮尿能力，临床用于治疗急迫性尿失禁、尿急、尿频等症状的膀胱过度活动症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1250745.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512943221","title":"【同和药业：获得韩国米拉贝隆药品注册证书】金融界2月17日消息，江西同和药业股份有限公司于近日收到韩国食品药品安全部颁发的米拉贝隆药品注册证书。公司为该药品的生产商，其产品获得此证书标志着获得了韩国市场的准入资格，将对公司扩大国际市场业务起到积极作用。但医药行业特点致使相关产品在国际市场的销售易受市场环境变化、汇率波动等因素影响。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512943221","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512943221?lang=zh_cn&edition=full","pubTime":"2025-02-17 18:21","pubTimestamp":1739787693,"startTime":"0","endTime":"0","summary":"金融界2月17日消息，江西同和药业股份有限公司于近日收到韩国食品药品安全部颁发的米拉贝隆药品注册证书。公司为该药品的生产商，其产品获得此证书标志着获得了韩国市场的准入资格，将对公司扩大国际市场业务起到积极作用。但医药行业特点致使相关产品在国际市场的销售易受市场环境变化、汇率波动等因素影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/17182148205582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","300636"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776437389129,"stockEarnings":[{"period":"1week","weight":0.0124},{"period":"1month","weight":0.0074},{"period":"3month","weight":0.0555},{"period":"6month","weight":-0.0204},{"period":"1year","weight":0.1714},{"period":"ytd","weight":0.0892}],"compareEarnings":[{"period":"1week","weight":0.0225},{"period":"1month","weight":0.0014},{"period":"3month","weight":-0.0113},{"period":"6month","weight":0.0562},{"period":"1year","weight":0.238},{"period":"ytd","weight":0.0218}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江西同和药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15461人(较上一季度减少3.02%)","perCapita":"23760股","listingDate":"2017-03-31","address":"江西省宜春市奉新县江西奉新高新技术产业园区","registeredCapital":"41995万元","survey":"　　江西同和药业股份有限公司的主营业务是化学原料药和医药中间体的研发、生产和销售。公司的主要产品是特色化学原料药及中间体、专利原料药及中间体。公司是技术驱动型企业，近三年研发投入平均占销售额的比例为8.34%，多次被认定为高新技术企业，先后获批组建了“江西省特色原料药工程技术研究中心”、“博士后科研工作站”、“江西省企业技术中心”、“江西省博士后创新实践基地”、“江西省新药研发产教融合创新中心”等技术创新平台，具有强大的研发能力和技术创新能力。","listedPrice":14.47},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"同和药业(300636)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供同和药业(300636)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"同和药业,300636,同和药业股票,同和药业股票老虎,同和药业股票老虎国际,同和药业行情,同和药业股票行情,同和药业股价,同和药业股市,同和药业股票价格,同和药业股票交易,同和药业股票购买,同和药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"同和药业(300636)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供同和药业(300636)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}